Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.

Detaylı Bibliyografya
Asıl Yazarlar:	Chopra, R, Goldstone, A, Buck, G, Richards, S, Franklin, I, Lazarus, H, Wiernek, P, Tallman, MS, Prentice, H, Durrant, J, Rowe, J
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	2003

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
Yazar:: Sive, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
Yazar:: Rowe, J, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993).
Yazar:: Rowe, J, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
Yazar:: Lazarus, H, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
Yazar:: Goldstone, A, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study
Yazar:: Goldstone, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)
Yazar:: Lazarus, H, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years.
Yazar:: Goldstone, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
Yazar:: Rowe, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Yazar:: Rowe, J, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
Yazar:: Goldstone, A, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
Yazar:: Marks, D, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Yazar:: Ganzel, C, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
Yazar:: Patel, B, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
Yazar:: Patel, B, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Yazar:: Goldstone, A, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Minimal residual disease is a significant predictor of treatment failure in B lineage adult ALL: final results of the international trial UKALL XII:ECOG 2993
Yazar:: Patel, B, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
Yazar:: Secker-Walker, L, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
Yazar:: Mansour, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
Yazar:: Moorman, A, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
Yazar:: Kumar, A, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties.
Yazar:: Chessells, J, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
Yazar:: Paietta, E, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.
Yazar:: Patel, B, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Yazar:: Fielding, A, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
Yazar:: Moorman, A, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials.
Yazar:: Chessells, J, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia: early results from the MRC UKALL12 Study
Yazar:: Patel, B, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Yazar:: Sive, J, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
Yazar:: Sive, J, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
Yazar:: Harrison, G, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol.
Yazar:: Mansour, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
Yazar:: Chessels, J, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.

Benzer Materyaller

Benzer Materyaller